{
  "id": "64402f6f57b1c7a315000045",
  "type": "list",
  "question": "What doses of RT001 were used in the phase I/II double-blind, comparator-controlled trial of Friedreich's ataxia patients?",
  "ideal_answer": "In the phase I/II double-blind, comparator-controlled trial of RT001 in Friedreich's ataxia patients two doses of the drug were evaluated 1.8 or 9.0 g/day.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29624723"
  ],
  "snippets": [
    {
      "text": "We conducted a phase I/II double-blind, comparator-controlled trial with 2 doses of RT001 in Friedreich's ataxia patients (9 subjects each cohort). Subjects were randomized 2:1 to receive either RT001 (1.8 or 9.0 g/day), or a matching dose of nondeuterated ethyl linoleate as comparator for 28 days.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29624723",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "1.8 g/day, 9.0 g/day"
}